UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription

Proceedings of the National Academy of Sciences - PNAS, 2002-09, Vol.99 (18), p.11593-11598

2002

Volltextzugriff (PDF)

The Dynamic Character of the G-Quadruplex Element in the c-MYC Promoter and Modification by TMPyP4

Journal of the American Chemical Society, 2004-07, Vol.126 (28), p.8702-8709

2004

Volltextzugriff (PDF)

Design and Synthesis of an Expanded Porphyrin That Has Selectivity for the c-MYC G-Quadruplex Structure

Journal of the American Chemical Society, 2005-03, Vol.127 (9), p.2944-2959

2005

Volltextzugriff (PDF)

Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element

Seminars in oncology, 2006-08, Vol.33 (4), p.498-512

2006

Volltextzugriff (PDF)

518 CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer

European journal of cancer supplements, 2010, Vol.8 (7), p.165-166

2010

Volltextzugriff (PDF)

99 Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models

European journal of cancer supplements, 2010, Vol.8 (7), p.39-39

2010

Volltextzugriff (PDF)

Conformationally Restricted Analogues of Psorospermin: Design, Synthesis, and Bioactivity of Natural-Product-Related Bisfuranoxanthones

Journal of medicinal chemistry, 2005-04, Vol.48 (8), p.2993-3004

2005

Volltextzugriff (PDF)

Effect of CX-4945, a selective bioavailable small molecule inhibitor of protein kinase CK2, on gemcitabine antitumor activity in A2780 ovarian cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13522-e13522

2010

Volltextzugriff (PDF)

Clinical development of CX-3543, a novel multi-targeting antitumor agent

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3206-3206

2005

Volltextzugriff (PDF)

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24), p.10288-10298

2010

Volltextzugriff (PDF)

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7653-7661

2009

Volltextzugriff (PDF)

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Journal of medicinal chemistry, 2011-01, Vol.54 (2), p.635-654

2011

Volltextzugriff (PDF)

Combined venetoclax and alvocidib in acute myeloid leukemia

Oncotarget, 2017-12, Vol.8 (63), p.107206-107222

2017

Volltextzugriff (PDF)

Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer

Biochemistry (Easton), 2011-10, Vol.50 (39), p.8478-8488

2011

Volltextzugriff (PDF)

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.994-1005

2012

Volltextzugriff (PDF)

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Molecular and cellular biochemistry, 2011-10, Vol.356 (1-2), p.37-43

2011

Volltextzugriff (PDF)

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer

Biochemical and biophysical research communications, 2011-11, Vol.415 (1), p.163-167

2011

Volltextzugriff (PDF)

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells

Cancer letters, 2012-09, Vol.322 (1), p.113-118

2012

Volltextzugriff (PDF)

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

ACS medicinal chemistry letters, 2012-07, Vol.3 (7), p.602-606

2012

Volltextzugriff (PDF)

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

ACS medicinal chemistry letters, 2012-02, Vol.3 (2), p.135-139

2012

Volltextzugriff (PDF)

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Cancer research (Chicago, Ill.), 2011-02, Vol.71 (4), p.1418-1430

2011

Volltextzugriff (PDF)

Abstract 5813: Pharmacodynamic biomarker strategies for CDK9 inhibition

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5813-5813

2020

Volltextzugriff (PDF)

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Blood, 2018-11, Vol.132 (Supplement 1), p.4355-4355

2018

Volltextzugriff (PDF)

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.3269-3269

2018

Volltextzugriff (PDF)

Abstract 4823: Alvocidib enhances the efficacy of cytarabine and daunorubicin (7+3) in non-clinical models of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4823-4823

2018

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Humans
(20)
Life Sciences & Biomedicine
(20)
Cell Line, Tumor
(13)
Animals
(11)
Biological And Medical Sciences
(10)
Casein Kinase Ii - Antagonists & Inhibitors
(10)
Chemistry, Medicinal
(10)
Mice
(10)
Pharmacology & Pharmacy
(10)
Chemistry
(9)
Oncology
(9)
Physical Sciences
(9)
Medical Sciences
(8)
Naphthyridines - Pharmacology
(8)
Antineoplastic Agents - Pharmacology
(7)
Neoplasms - Drug Therapy
(7)
Pharmacology. Drug Treatments
(7)
Structure-Activity Relationship
(7)
Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription

The Dynamic Character of the G-Quadruplex Element in the c-MYC Promoter and Modification by TMPyP4

Design and Synthesis of an Expanded Porphyrin That Has Selectivity for the c-MYC G-Quadruplex Structure

Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element

518 CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer

99 Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models

Conformationally Restricted Analogues of Psorospermin: Design, Synthesis, and Bioactivity of Natural-Product-Related Bisfuranoxanthones

Effect of CX-4945, a selective bioavailable small molecule inhibitor of protein kinase CK2, on gemcitabine antitumor activity in A2780 ovarian cancer

Clinical development of CX-3543, a novel multi-targeting antitumor agent

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Combined venetoclax and alvocidib in acute myeloid leukemia

Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Abstract 5813: Pharmacodynamic biomarker strategies for CDK9 inhibition

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Abstract 4823: Alvocidib enhances the efficacy of cytarabine and daunorubicin (7+3) in non-clinical models of acute myeloid leukemia

Suchergebnisse filtern